These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD-L1 expression and tumor-infiltrating lymphocytes. Chen L; Cao MF; Zhang X; Dang WQ; Xiao JF; Liu Q; Tan YH; Tan YY; Xu YY; Xu SL; Yao XH; Cui YH; Zhang X; Bian XW Cancer Med; 2019 Dec; 8(17):7207-7218. PubMed ID: 31605439 [TBL] [Abstract][Full Text] [Related]
3. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma. Yeo MK; Choi SY; Seong IO; Suh KS; Kim JM; Kim KH Hum Pathol; 2017 Oct; 68():103-111. PubMed ID: 28851662 [TBL] [Abstract][Full Text] [Related]
4. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas. Driver BR; Miller RA; Miller T; Deavers M; Gorman B; Mody D; Ge Y; Barrios R; Bernicker E; Kim M; Cagle PT Arch Pathol Lab Med; 2017 Nov; 141(11):1529-1532. PubMed ID: 28829153 [TBL] [Abstract][Full Text] [Related]
5. The immune microenvironment in non-small cell lung cancer is predictive of prognosis after surgery. Öjlert ÅK; Halvorsen AR; Nebdal D; Lund-Iversen M; Solberg S; Brustugun OT; Lingjaerde OC; Helland Å Mol Oncol; 2019 May; 13(5):1166-1179. PubMed ID: 30854794 [TBL] [Abstract][Full Text] [Related]
6. Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations. Toki MI; Mani N; Smithy JW; Liu Y; Altan M; Wasserman B; Tuktamyshov R; Schalper K; Syrigos KN; Rimm DL J Thorac Oncol; 2018 Dec; 13(12):1884-1896. PubMed ID: 30267840 [TBL] [Abstract][Full Text] [Related]
8. Expression of phosphatase and tensin homolog and programmed cell death ligand 1 in adenosquamous carcinoma of the lung. Hlaing AM; Furusato B; Udo E; Kitamura Y; Souda M; Masutani M; Fukuoka J Biochem Biophys Res Commun; 2018 Sep; 503(4):2764-2769. PubMed ID: 30100056 [TBL] [Abstract][Full Text] [Related]
9. Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples. Casadevall D; Clavé S; Taus Á; Hardy-Werbin M; Rocha P; Lorenzo M; Menéndez S; Salido M; Albanell J; Pijuan L; Arriola E Clin Lung Cancer; 2017 Nov; 18(6):682-691.e5. PubMed ID: 28549836 [TBL] [Abstract][Full Text] [Related]
10. Association of PD-1, PD-L1, and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients With Non-Small-Cell Lung Cancer. Lafuente-Sanchis A; Zúñiga Á; Estors M; Martínez-Hernández NJ; Cremades A; Cuenca M; Galbis JM Clin Lung Cancer; 2017 Mar; 18(2):e109-e116. PubMed ID: 27816393 [TBL] [Abstract][Full Text] [Related]
11. The Landscape of Actionable Molecular Alterations in Immunomarker-Defined Large-Cell Carcinoma of the Lung. Chan AW; Chau SL; Tong JH; Chow C; Kwan JSH; Chung LY; Lung RW; Tong CY; Tin EK; Law PP; Law WT; Ng CSH; Wan IYP; Mok TSK; To KF J Thorac Oncol; 2019 Jul; 14(7):1213-1222. PubMed ID: 30978501 [TBL] [Abstract][Full Text] [Related]
12. Genomic Copy Number Signatures Uncovered a Genetically Distinct Group from Adenocarcinoma and Squamous Cell Carcinoma in Non-Small Cell Lung Cancer. Lee E; Moon JW; Wang X; Kim C; Li S; Shin BK; Jung W; Kim HK; Kim HK; Lee JY Hum Pathol; 2015 Aug; 46(8):1111-20. PubMed ID: 26003479 [TBL] [Abstract][Full Text] [Related]
13. Insights into the heterogeneity of the tumor microenvironment in lung adenocarcinoma and squamous carcinoma through single-cell transcriptomic analysis: Implications for distinct immunotherapy outcomes. Fang X; Li D; Wan S; Hu J; Zhang P; Jie D; Chen L; Jiang G; Song N J Gene Med; 2024 Jun; 26(6):e3694. PubMed ID: 38847309 [TBL] [Abstract][Full Text] [Related]
14. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study. Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075 [TBL] [Abstract][Full Text] [Related]
15. A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell Carcinoma. Matsubara T; Takada K; Azuma K; Takamori S; Toyokawa G; Haro A; Osoegawa A; Tagawa T; Kawahara A; Akiba J; Okamoto I; Nakanishi Y; Oda Y; Hoshino T; Maehara Y Ann Surg Oncol; 2019 Jun; 26(6):1925-1933. PubMed ID: 30815803 [TBL] [Abstract][Full Text] [Related]
16. Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies. Dong ZY; Zhang C; Li YF; Su J; Xie Z; Liu SY; Yan LX; Chen ZH; Yang XN; Lin JT; Tu HY; Yang JJ; Zhou Q; Sun YL; Zhong WZ; Wu YL J Thorac Oncol; 2018 Jan; 13(1):85-96. PubMed ID: 29127022 [TBL] [Abstract][Full Text] [Related]